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One Sentence Summary:  
Daily energy restriction more effectively reduces body fat content than alternate-day fasting, 
with no evidence of fasting-specific health benefits.  
Abstract:  
Intermittent fasting may impart metabolic benefits independent of energy balance by initiating 
fasting-mediated mechanisms. This randomized controlled trial examined 24-h fasting with 
150% energy intake on alternate days for 3 weeks (0:150; n=12). Control groups involved a 
matched degree of energy restriction applied continuously without fasting (75% energy intake 
daily; 75:75; n=12) or a matched pattern of fasting without net energy restriction (200% energy 
intake on alternate days; 0:200; n=12). Primary outcomes were body composition, components 
of energy balance, and post-prandial metabolism. Daily energy restriction (75:75) reduced body 
mass (-1.910.99 kg) almost entirely due to fat loss (-1.750.79 kg). Restricting energy intake 
via fasting (0:150) also decreased body mass (-1.601.06 kg; p=0.46 versus 75:75) but with 
attenuated reductions in body fat (-0.741.32 kg; p=0.01 versus 75:75), whereas fasting without 
energy restriction (0:200) did not significantly reduce either body mass (-0.521.09 kg; p≤0.04 
versus 75:75 & 0:150) or fat mass (-0.120.68 kg; p≤0.05 versus 75:75 & 0:150). Post-prandial 
indices of cardiometabolic health and gut hormones, along with the expression of key genes in 
subcutaneous adipose tissue, were not statistically different between groups (p>0.05). Alternate-
day fasting less effectively reduces body fat mass than a matched degree of daily energy 
restriction and without evidence of fasting-specific effects on metabolic regulation or 






Intermittent fasting is an umbrella term for dietary regimens involving temporal 
restriction of daily feeding patterns, including a fast on some days each week (for example the 
“5:2” diet), for part of each day (time-restricted feeding) or for part or all of every second day 
(modified/complete alternate-day fasting; 1). The apparent popularity of these approaches 
suggests that many people find adoption and adherence comparatively easy, potentially because 
we as a species are well adapted to erratic food availability as opposed to an abundant food 
supply and thus permanently post-prandial (fed) and lipogenic state throughout waking hours (2, 
3). As neatly described previously, all mammals exhibit evolutionarily conserved (albeit 
somewhat species-specific) adaptive responses to food deprivation (4). Specifically, fasting-
mediated mechanisms stimulate lipolysis and ketogenesis to support energy requirements, whilst 
regulating various cell signalling pathways to efficiently recycle the limited nutrients available 
(reduced glycolysis and protein synthesis, with increased autophagy; 4, 5, 6).  
Studies in mice clearly demonstrate that metabolic health can be improved by restricting 
food availability to certain periods (independent of energy intake or weight loss), although such 
fasting deviates more profoundly from these animals’ naturally continuous foraging pattern than 
from the schedule of regular but less frequent meals more typical of human societies (7). Recent 
reviews of human trials indicate that intermittent fasting can elicit weight loss and health gains 
but that these effects are generally equivalent to standard energy restriction without restricted 
feeding times (that is, without fasting), indicating that metabolic effects may be due to weight 
loss rather than fasting per se (1, 8-10). However, trials to date have generally involved 
substantial reductions in energy intake but without prescribing complete abstinence from 





mediated mechanisms (11). Indeed, at least 12-14 consecutive hours of absolute nutritional 
withdrawal is required to elicit frank depletion of hepatic glycogen reserves and the consequent 
transition towards oxidation of endogenous lipid-derived substrates (fatty acids and ketone 
bodies; 12, 13), which are proposed to increase insulin sensitivity, improve cardiovascular 
health, and preserve muscle mass during weight loss (4, 14). 
Based upon the above reasoning, it becomes understandable why the small minority of 
human trials that have reported positive health outcomes peculiar to intermittent fasting (beyond 
that explained by weight loss) are those same few in which the post-absorptive state has been 
regularly sustained via uninterrupted fasting of at least 16 h (1). For example, early time-
restricted feeding (fasting from 1500 h daily) in men with pre-diabetes improved their insulin 
sensitivity within five weeks without losing weight, simply by extending their usual overnight 
fast to 18 h (15). This effect on insulin sensitivity has since been confirmed in healthy young 
adults after just 2 weeks of fasting for 16 h from 1600 h each day (16) and after 8 weeks of 
simply restricting typical daily meals to an 11-h period ending at 1900 h (17). The other common 
form of intermittent fasting that routinely involves such protracted post-absorptive periods is 
complete alternate-day fasting (no energy intake whatsoever during fasting days), yet almost no 
research has examined fasting periods that span an entire day. One recent trial has shown that 
strict ~36 h fasting periods alternated with ~12-h ad libitum eating every other day can markedly 
reduce both fat mass and cardiovascular disease risk markers amongst non-obese adults within 
four weeks (18). However, that study did not include the continuous energy restriction control 
group necessary to dissociate the effects of fasting from the net energy deficit, as has been 
effectively applied previously in demonstrating the absence of independent benefits inherent to 





Given that intermittent fasting is hypothesized to exert independent benefits via fasting-
mediated mechanisms, it is remarkable that only one previous human trial has attempted to 
isolate such effects by extending the post-absorptive period sufficient to fully initiate those 
mechanisms (a complete 24-h cycle). That study examined insulin-sensitivity by 
hyperinsulinemic-euglycemic clamp rather than examining the response to ingested nutrients or 
the effect on components of energy balance, revealing that 24-h fasting for three non-consecutive 
days each week reduced fat mass, blood lipids and fasted insulin more effectively than either 
continuous energy restriction or fasting without energy restriction in women with overweight 
(21). The present study provides insight using a comprehensive experimental design that 
contrasts strict alternate-day fasting both with and without weight loss relative to a continuous 
energy restriction control, thus isolating the independent and combined effects of fasting and 
dietary energy restriction on measures of body composition, components of energy balance, post-
prandial markers of metabolic health, and subcutaneous adipose tissue gene expression (for full 
protocol see 22). This focus on prolonged fasting but with controlled compensatory refeeding 
therefore addresses fundamental questions about whether this popular form of intermittent 
fasting improves body composition and metabolic health independent of energy balance and 
weight loss. We hypothesized that intermittent fasting would result in compensatory inhibition of 







Alternate-day fasting was no more or less effective than a matched degree of daily energy 
restriction in reducing body mass. However, whereas daily energy restriction (75:75) elicited 
weight loss almost entirely by reducing body fat mass, weight loss via alternate-day fasting 
(0:150) was due in equal measure to reductions in both fat and fat-free mass (Table 1 and 
Figure 1A). These body composition data correspond to pre-post group differences (group x 
time interaction p<0.0001) in meanSD percent body fat of -1.80.9 % when restricting energy 
daily (75:75; p<0.0001) but only -0.61.1 % or 0.10.9 % when alternate-day fasting with 
(0:150) or without (0:200) matched energy restriction, respectively (p=0.10 & p=0.69). 
However, this pattern was not apparent for visceral fat mass, which was reduced by a similar 
extent irrespective of whether energy restriction was applied continuously or intermittently (time 
p=0.003, group x time interaction p=0.30; Table 1).  
 
Components of Energy Balance 
The energy ingested in the form of each dietary macronutrient is presented in Figure 1B, 
as reported during the baseline monitoring phase and then each intervention. These changes in 
energy intake from baseline were different between groups, consistent with the prescribed 
experimental model (group x time interaction p<0.0001). Furthermore, the group who were 
asked to fast but without reducing their net energy intake (0:200) appear to have managed to do 
so accurately, thus facilitating the intended analysis of fasting independent of energy restriction 





The various components of energy expenditure (resting metabolic rate, diet-induced 
thermogenesis and physical activity thermogenesis) are illustrated in Figure 1C and show group 
differences for total energy expenditure (group x time interaction p=0.004) due to a decrease 
from baseline only when alternate-day fasting was combined with energy restriction (0:150; 
p=0.002), with post-hoc analysis revealing a specific difference in this response relative to the 
group which fasted without net energy restriction (0:200; p<0.003). Figure 1C shows that this 
pattern for total energy expenditure [kcal·d-1] is partly attributable to a slight but variable 
reduction in resting metabolic rate (time p=0.18, group x time interaction p=0.19; time effects 
with no differences between groups were apparent for basal/fasted rates [g·min-1] of 
carbohydrate and lipid oxidation p=0.02 & p=0.01, respectively – see data file S1) and partly due 
to a consistent but predictable fall in diet-induced thermogenesis based on reported 
macronutrient intake (group x time interaction p=0.004). Accordingly, the reductions in diet-
induced thermogenesis with energy restriction applied either daily (75:75; p<0.0001) or every 
other day (0:150; p=0.0002) were necessarily proportionate to the prescribed reduction in energy 
intake.  
Figure 1D presents data for post-prandial substrate oxidation following the standardized 
breakfast consumed before and after the intervention; the total amount of energy expended 
during the 3 h post-prandial period was systematically reduced by a similarly small amount (7  
16 kilocalories over 180 minutes) in all groups (time p=0.02), with no differences between 
groups (group x time interaction p=0.36). However, whereas the overall rate of substrate 
oxidation was not affected by fasting alone or in combination with weight loss, the rate of lipid 





groups (0:150 & 0:200) relative to the daily energy restriction group (75:75; group x time 
interaction p=0.047). 
In terms of physical activity thermogenesis, we observed divergent behavioural responses 
to fasting and energy restriction (group x time interaction p=0.04; Figure 1E), albeit without any 
post-hoc differences observed between pairwise group contrasts. Specifically, restricting energy 
intake via alternate-day fasting (0:150) resulted in a compensatory reduction in physical activity 
thermogenesis, primarily due to reduced spontaneous light- and moderate-intensity movements, 
whereas no such reductions in activity were apparent during daily energy restriction (75:75) or 
alternate-day fasting without energy restriction (0:200). Figure 1F shows an exploratory analysis 
of how the overall ~100 kcal·d-1 reduction in physical activity energy expenditure when fasting 
with net energy restriction (0:150) was predominantly due to lower activity during fasting 
periods (especially when they occurred in the second half of the day), although there was also 
evidence of reduced activity during fed periods (especially when they occurred during the first 
part of the day).  
 
Post-Prandial Metabolism 
None of the dietary interventions differentially affected fasted concentrations or post-
prandial responses of plasma glucose, insulin, non-esterified fatty acids, glycerol, total 
cholesterol or the fractions of either high- or low-density lipoprotein cholesterol (Table 2, 
Figures 2 & 3). Although fasted triacylglycerol concentrations did not respond differently 
between treatments, the total area under curve did exhibit pre-post group differences reflecting 
an increase when energy was restricted daily (75:75) relative to a decrease when energy was 





 Group differences were apparent in the pre-post response of plasma leptin concentrations 
(group x time interaction p=0.04), with the greatest decrement in the daily energy restriction 
group (75:75; Table 2). In contrast to these clear effects on leptin, neither energy restriction nor 
fasting exerted any influence on the plasma concentrations of adiponectin under overnight fasted 
conditions (Table 2) or on the acute response of acylated ghrelin and peptide YY to the two 
sequential mixed-meal tolerance tests (Figure 3C and Figure 3D). There were no differences in 
fasted or postprandial plasma CTX concentrations throughout the laboratory visits pre- and post-
intervention (Figure 3B) nor any group differences in bone mineral density (Table 1).  
Overall, of the various genes pre-selected on the basis of their involvement in biological 
rhythms and metabolic responses to feeding, the relative changes in mRNA from pre- to post-
intervention did not indicate a clear response either within or between groups (Figure 4). This 
was evident both in the general absence of significant group x time interactions and by the fact 
that the fold-changes observed in the raw data were similar in absolute terms between groups 
(see data file S1). Nonetheless, it should be noted that significant group x time interactions 
(p≤0.05) were apparent for CEBPB (CCAAT-Enhancer Binding Protein-β), IRS2 (Insulin 
Receptor Substrate 2), PER1 (Period Circadian Regulator 1) and PPARGC1A (Peroxisome 
Proliferator-Activated Receptor γ Coactivator 1-α), of which post-hoc analysis indicated 








The present study indicates that alternate-day fasting is less effective for reducing body 
fat content than a matched degree of energy restriction applied daily without fasting in lean 
healthy adults. This difference in fat loss despite a standardized reduction in energy intake may 
be at least partly explained by the compensatory decrease in energy expenditure within the group 
who restricted energy intake via fasting (primarily due to inhibition of physical activity 
thermogenesis), although this effect did not differ significantly from the other groups who did 
not on average reduce their physical activity. However, other than an adaptive reduction in fasted 
concentrations of plasma leptin proportionate to changes in fat mass, there were no meaningful 
effects of fasting or energy restriction (independently or combined) on systemic markers of 
cardiometabolic health or gut hormone responses to sequential meals. There were also no clear 
fasting-specific patterns in the expression of key genes in subcutaneous adipose tissue. 
It has been a matter of ongoing debate whether intermittent as opposed to continuous 
energy restriction either preserves lean mass during weight loss (23, 24) or favours greater 
muscle protein breakdown and net catabolism (8, 25). Although changes in fat-free mass were 
not significantly different between groups in the current study, our data certainly do not support 
any relative preservation of lean mass when fasting but rather are more consistent with the 
possibility that complete fasting for a prolonged period every other day (0:150) is not conducive 
to the retention of lean mass under conditions of net energy deficit. That interpretation would be 
in agreement with recent trials that have reported reductions in fat-free mass even with modified 
alternate-day fasting that does not require such extended periods without food (25% of energy 
requirements allowed on fasting days), albeit also no differently than daily energy restriction in 





reductions in fat-free mass can be offset by only slightly increasing the daily fasting period from 
18-20 h (27). It therefore appears that losses of fat-free mass are possible even with less 
protracted periods of limited nutrient delivery than implemented in the present study and so 
further research is needed to examine the potential for a more sustained catabolic state to result 
in atrophy of lean soft tissue mass or indeed to improve anabolic sensitivity (16).  
Although lean soft tissue mass includes components such as water, glycogen and the non-
lipid component of adipose tissue (the latter being automatically reduced by fat loss; 28), pre-
scan fluid and food intake were carefully standardized in this experiment and any remaining 
effect on the lean portion of adipose tissue would be relatively minor. Indeed, a recent trial 
reported that late time-restricted feeding (fasting 2000-1200 h daily) reduced appendicular fat-
free mass in particular, which probably reflects losses specific to skeletal muscle (29). It 
therefore remains a possibility that at least some of the individuals who were restricting energy 
intake via alternate-day fasting in the present study were experiencing a reduction in skeletal 
muscle mass, which might erroneously be interpreted as successful dieting if using common 
weighing scales. Losing metabolically active fat-free mass (especially skeletal muscle) is 
generally an undesirable outcome for physical function, cardiometabolic health, and for 
sustaining an energy deficit with minimal adaptation in metabolic requirement. Instead, 
intermittent fasting is generally adopted by individuals hoping to achieve weight loss in terms of 
reducing body fat content and yet the present study clearly illustrates that continuous daily 
energy restriction is more effective in achieving that outcome. It is notable, however, that 
visceral fat mass responded similarly to intermittent versus continuous energy restriction, as that 





cardiometabolic risk and with the sub-cutaneous fat depot that did respond so differently to the 
interventions in this study (30). 
In terms of metabolic rate, it is noteworthy that there was not a larger or more consistent 
difference between groups either under basal/fasted conditions or in response to breakfast - 
especially given that fasting and energy restriction differentially affected changes in both body 
mass and composition, which automatically dictate metabolic requirements. Notably, this finding 
persists irrespective of whether the rates of metabolism and substrate oxidation are expressed in 
absolute terms (kcal·d-1 and g·min-1) or relative to either body mass or fat-free-mass; any effect 
of fasting or energy restriction in terms of adaptive thermogenesis is therefore likely to be small 
and not markedly different between groups. 
Beyond the above relatively trivial responses of resting metabolic rate and diet-induced 
thermogenesis, a major focus of this experiment and an important potential contributor to the 
decrement in total daily energy expenditure is the compensatory behavioural response. Indeed, 
the energy expended via physical activity is the most variable and malleable component of 
energy expenditure and thus has the greatest potential to undermine an imposed energy 
restriction. It is therefore surprising that no past research had objectively quantified the response 
of this variable specific to alternate-day fasting. Several past studies have monitored aspects of 
physical activity during other forms of intermittent fasting but even these few studies were 
designed to focus on isolating metabolic responses and so tended to advise participants not to 
consciously alter their physical activity during the interventions (20, 21, 31, 32). However, 
structured exercise is only one aspect of physical activity and sub-conscious behavioural 
adaptations in non-exercise activity thermogenesis (NEAT) are an important compensatory 





In the present study we objectively quantified all aspects of exercise and non-exercise 
physical activity thermogenesis under free-living conditions in which participants were given to 
understand that, far from consciously avoiding unplanned behaviour changes, they should 
behave naturally. Our observation of reduced physical activity when restricting energy intake via 
alternate-day fasting but without any such reductions when energy restriction or fasting were 
applied separately is inconsistent with a recent trial that found activity energy expenditure to be 
very stable during 4 weeks of alternate-day fasting relative to a non-intervention control group 
(thus not matched for energy restriction; 18) or after two weeks of early time-restricted feeding 
(16). However, behavioural compensation has been noted in past trials involving weight loss or 
daily caloric restriction but without fasting (33). In terms of isolating the effect of fasting per se 
on physical activity, two previous investigations into daily breakfast omission in lean and obese 
adults corroborate the current findings given that light- and moderate-intensity physical activity 
were also lower with extended fasting in those studies, particularly during the morning period 
when participants were post-absorptive (34, 35). Here we used the same tool to objectively 
measure physical activity thermogenesis and so it is similarly possible to explore the temporal 
pattern of behavioural compensation specific to fasted and fed periods. 
To consider what might explain the apparent differences in physical activity, it is 
important to note that the responses to the intervention cannot be explained simply by reactive 
changes in the times participants rose in the morning or went to bed at night depending on 
whether they were fasting, because these times remained within six minutes of the times 
recorded at baseline. Equally, the energy expended directly preparing (or not preparing) food is 
unlikely to account for overall changes in physical activity as the overall energetic contribution 





tachycardia may respectively explain the lower energy expenditure with fasting or the higher 
energy expenditure when refeeding (particularly considering the increase in physical activity 
specific to fed periods in the group who avoided energy restriction). This is also unlikely, 
however, because extreme (even maximal) overeating only increases resting heart rate by ~6 
beats·min-1 in the immediate post-prandial period (37) and by ~2 beats·min-1 after a week of 
energy surplus (38). Recent work has also now reported anticipatory behavioural modification 
even outside the period of dietary intervention, which cannot therefore be attributed to changes 
in heart rate during the fast (39). Moreover, the changes in physical activity reported here were 
all primarily due to light- and moderate-intensity movements, for which the branched model 
equations used to calculate energy expenditure are weighted heavily towards accelerometry 
unless heart rate is increased markedly above rest.  
It therefore seems reasonable to conclude that behavioural compensation in low-to-
moderate intensity physical activity is indeed responsible for the divergent responses of physical 
activity thermogenesis between groups in this study, consistent with the hypothesis that sub-
conscious engagement in spontaneous movements is reduced by the interaction of alternate-day 
fasting with weight loss but not by fasting per se. This may therefore be a direct influence of low 
nutrient availability due to fasting, although our results indicate that not all the reduction in 
physical activity occurred during fasting periods (with some reduction in energy expenditure 
during fed periods, especially when they occurred during the first part of the day). The latter may 
indicate an anticipatory reduction in physical activity behaviours in advance of the impending 
dietary restriction (39). Future research is therefore warranted to examine both whether there is 





morning feeding and also whether early- or late-time restricted feeding may differ in their 
potential to elicit this behavioural response. 
Understanding the effects of intermittent fasting on post-prandial metabolic control has 
recently been identified as a research priority (1, 9). Post-prandial measures provide a better 
indication of disease risk than basal/fasted blood samples (40, 41), and simultaneously provide a 
more valid reflection of the fed state that generally predominates for the majority of each 24-h 
cycle (2, 3). Notably, the few studies to have begun examining meal responses to intermittent 
fasting diets have identified clear benefits in terms of reducing post-prandial glycemia (42), 
insulinemia (15) and triglyceridemia (43), albeit without any improvement in whole-body insulin 
sensitivity whether assessed via hyperinsulinemic-euglycemic clamp (21) or oral glucose 
tolerance test (44). Most recently, however, early time-restricted feeding was shown to improve 
post-prandial skeletal muscle glucose and branched-chain amino acid uptake in healthy men 
independent of weight loss (16). In view of these recent findings, it is notable that fasted and 
post-prandial metabolites were generally unresponsive to energy restriction in the present study, 
particularly in light of the post-prandial substrate oxidation data, which indicated that the fasting 
interventions increased post-prandial lipid oxidation.  
One possible explanation for the absence of response in relation to systemic indices of 
cardiometabolic health in this study is that an intervention longer than three weeks may be 
required to elicit meaningful changes in these outcomes, although it has been argued that such 
responses are usually evident within 2-4 weeks (4). That latter interpretation would certainly be 
consistent with recent studies of intermittent fasting that show effects on insulin sensitivity and 
glycemic control within 1-5 weeks (15, 42). A more likely reason why markers of 





that participants were not overweight at baseline. Specifically, positive effects of energy 
restriction on metabolic profile may be secondary to clearance of ectopic lipids (45), which may 
not yet have accumulated substantially in the ostensibly healthy individuals tested here. Further 
research should therefore repeat this experiment in an overweight or obese population. 
Leptin is secreted from adipose tissue in proportion to fat mass (46). It is therefore 
understandable that the varied decrements in fat mass observed in the two energy restriction 
trials in this study (75:75 & 0:150) were mirrored by group differences in the pre-post response 
of fasted concentration of plasma leptin. This pattern is consistent with the physiological role of 
leptin as part of a negative feedback loop to sustain endogenous energy reserves in the face of 
sustained negative energy balance (47), thus validating the established relationship between 
leptin and fat mass irrespective of whether weight loss is elicited by continuous energy 
restriction or intermittent fasting. It might therefore be speculated that the greater fat loss in the 
daily energy restriction group (75:75) might lower satiety more so than the alternate-day fasting 
groups in order to minimise further reductions in fat mass or even restore the lost energy 
reserves. When considering this effect on leptin alongside the absence of group differences in 
acylated ghrelin and peptide YY, it appears that that energy restriction can elicit an adaptive 
neuroendocrine response via the basal concentration of tonic (longer-term) satiety hormones 
such as leptin but without compensation in the acute concentrations of episodic appetite 
hormones to daily meals, although leptin may act synergistically to potentiate the response of 
acute hormones (48, 49). 
Although not pre-specified as an outcome measure in our clinical trial registration 
(www.clinicaltrials.gov NCT02498002), an opportunity arose to measure plasma concentrations 





resorption, thus allowing an exploratory analysis of bone turnover with intermittent fasting 
relative to the bone mineral density data obtained from the DXA scans in this study. Our 
observation that neither plasma CTX or bone mineral density differed between treatments may 
simply reflect that it requires longer than 6 months to reveal measurable changes in bone 
turnover via DXA, yet even 6 months of alternate-day fasting does not appear to alter bone 
mineral density or fasted plasma CTX concentrations (50). Nonetheless, CTX rapidly responds 
to under 4 weeks of intensive exercise with restriction and subsequent replacement of 
carbohydrate alone (even without net energy restriction; 51). It may therefore be that the 
additional stimulus of exercise and restriction of carbohydrate in particular may be required to 
alter bone metabolism during interventions lasting only a few weeks. 
To the authors’ knowledge, this trial provides a report of gene expression in human 
adipose tissue within the context of alternate-day fasting. Rather than interpreting the ostensible 
response of a few genes in isolation, illustrating such data using a heat map renders it possible to 
consider the overall pattern of responses across all the genes that operate in concert. From that 
perspective, it may be worth noting that fasting with net energy restriction (0:150) indicates 
consistent downregulation of almost all genes analyzed, with the few exceptions that were 
markedly upregulated all being the same genes that are markedly downregulated after fasting 
without net energy restriction (0:200) and also all implicated in inflammation (CEBPB, 
NAMPT/visfatin & Tumor Necrosis Factor-α). These few observations notwithstanding, the 
overall lack of effects on gene expression in the present study of lean individuals may indicate 
that fasting and energy restriction for several weeks do not exert any substantial influence at the 
genetic level in human subcutaneous adipose tissue. This absence of effect may therefore be 





(but not core clock genes) in response to time-restricted feeding (52). It may be that any effects 
of fasting on adipose tissue gene expression are short-lived and so do not persist following even 
one day of habitual energy intake, which in the present study was standardized within each 
participant 24 h prior to follow-up samples in order to replicate conditions preceding the 
corresponding baseline samples. Alternatively, a more prolonged or intensive intervention that 
elicits more profound reductions in fat mass may be necessary before effects on adipose tissue 
gene expression can be detected. 
There are several limitations to our study that arise primarily due to the practical 
constraints inherent to intensive human intervention trials. Although groups were well-matched 
for physiological characteristics at baseline, the proportion of males and females was not equal 
between groups (table S1) and the sample size was slightly reduced for adipose tissue gene 
expression as adipose biopsies were an optional procedure for which few volunteered (although 
the small/similar absolute fold-changes in gene expression indicate that no physiologically 
meaningful differences have gone undetected simply due to statistical power). Similarly, no 
participants elected to provide skeletal muscle biopsies; measures of muscle protein synthesis 
would have been informative in view of the fat-free mass data reported here. In relation to the 
free-living intervention, it should be acknowledged firstly that compliance was self-reported (so 
would have benefitted from objective verification via continuous glucose monitoring; 34, 35) 
and secondly that additional effects may have become evident had it been feasible to sustain this 
intervention beyond 3 weeks. The post-prandial measures of triacylglycerol and glycerol should 
also be interpreted with caution because a high degree of variability was apparent in measured 
values, yet the effects reported here in relation to triacylglycerol total area under curve are 





reduced post-prandial triglyceridemia (43). Last, not all metabolic responses to the second meal 
had returned to basal levels within the 2-h post-prandial measurement period. It would therefore 
be interesting to have extended the monitoring period later into the evening and, ideally, to have 
documented a complete 24-h diurnal cycle. 
The fact that intermittent fasting exerted no greater effect than continuous daily energy 
restriction on anthropometric, metabolic, and behavioural outcomes in this study may in part be a 
consequence of the alternating daily nature of the fasting periods. Specifically, the transition 
between fasted and fed states at 1500 h on alternate days may not be conducive to the 
entrainment of diurnal rhythms within the human circadian timing system; the signalling effects 
of high or low nutrient availability may then be compromised because metabolic and behavioural 
food anticipatory activity cannot be aligned to a regular meal pattern in each daylight period 
(53). It may therefore be that intermittent fasting models such as alternate-day fasting or the 
“5:2” diet that do not repeat every 24 hours necessarily have less potential to optimise 
physiological function than models in which fasting is scheduled at the same time each day (such 
as time-restricted feeding). However, given that human physiology operates to defend against the 
desired energy deficit that is the objective of dieting, there may still be some value in 
deliberately misaligning and thus impairing that natural protective response via a more erratic 
fasting schedule - perhaps in overweight or obese individuals for whom there is more excess 
body fat to lose or pre-existing health conditions to rectify. 
Although the intermittent fasting regimen employed here was inferior for reducing body 
fat relative to daily energy restriction in terms of our completers-only analysis, participants 
allocated to the 0:150 group nonetheless appeared to find adoption and adherence reasonably 





more modest reductions in adiposity. Alternate-day fasting may still therefore represent a viable 
even if sub-optimal weight loss option for those who find this pattern relatively easy to adopt and 
adhere to within their wider lifestyle, perhaps in combination with countermeasures targeting 
lean tissue mass (such as resistance exercise). Even accepting that alternate-day fasting may not 
be sufficiently feasible in the specific form described here or may not be justified by the overall 
risk-benefit analysis, an improved basic science understanding of intermittent fasting can inform 
related approaches (development of novel ingredients, periodization of particular nutrients or 
exercise, fasting mimicking diets, and so on) with a view to maximizing potential advantages 
whilst minimizing any disadvantages. 
In summary, for lean healthy adults, continuous daily energy restriction (traditional diet 
advice) results in meaningful weight loss that is almost entirely attributable to reduced adipose 
tissue mass. By contrast, using alternate-day fasting to elicit the same energy deficit can 
spontaneously inhibit physical activity relative to the usual pre-diet engagement in such 
behaviour and so less effectively reduces fat mass than continuous daily energy restriction. These 
are generally undesirable responses linked to poor long-term health outcomes, although no short-
term changes in metabolic health were apparent in the lean population reported here. The main 
practical message for individuals to consider if planning to use alternate-day fasting for the 
purpose of weight loss or health gain is thus to consciously insert opportunities for physical 
activity alongside the intermittent fasting regimen in order to maintain energy expenditure and 





Materials and Methods 
Study Design 
We conducted a randomized controlled trial in which 36 lean healthy adults were 
randomly allocated into three experimental conditions following a 4-week baseline monitoring 
phase (habitual diet and physical activity). One group (n=12) served as a continuous dietary 
energy restriction control by being prescribed 75% of their habitual energy intake each day (25% 
daily energy restriction; 75:75); a second group (n=12) were prescribed a matched degree of 
dietary energy restriction but achieved via alternating 24-h periods of complete fasting and 
consuming 150% of their habitual energy intake (25% net energy restriction; 0:150); a third 
group (n=12) were prescribed a matched pattern of complete fasting every other 24 hours but 
consuming 200% of their habitual energy intake on fed days (no net dietary energy restriction; 
0:200).  
Critically, the two fasting groups (0:150 & 0:200) consumed no energy-providing 
nutrients whatsoever during fasting periods and transitioned from fasted to fed state and vice 
versa at 1500 h on a daily basis. This time was selected for a number of reasons: it provides a 
consistent fasting duration of precisely 24 h, thus sufficient to elicit the desired fasting-mediated 
mechanisms whilst also standardized between fasted and fed periods (rather than a more variable 
fasting duration if dictated by sleep times); our recent work revealed diurnal rhythms in human 
skeletal muscle transcriptomics and lipidomics that exhibit peak accumulation of relevant gene 
transcript and lipid metabolites at 1600 h (54, 55), so the metabolic switch between the fed and 
fasted state would be complete by 1600 h each day (11); effects can be attributed to fasting as 
opposed to any systematic shift in circadian rhythms because the time-restricted feeding 





approximately the mid-point of each waking period, allowing equally weighted contrasts 
between the metabolic and behavioural responses in each half of the day; and our pilot testing 
suggests that participants find it relatively feasible to fast for this duration given that there is no 
complete waking period without food. 
In terms of outcome measures, recent reviews on this topic have highlighted the need for 
trials investigating the components of energy balance under free-living conditions in order to 
understand the distinct compensatory metabolic and behavioural responses to fasting per se as 
opposed to mere energy restriction (1, 9). In particular, there is an outstanding need to establish 
the effects of regularly fasting for an extended period on the preservation of fat-free mass (and 
thus resting metabolic rate during weight loss); compensatory behavioural adjustments in 
physical activity thermogenesis; and alterations in metabolic control both under fasted conditions 
and in the fed state. Below we therefore present data for three primary outcomes, namely 
changes in body composition, components of energy balance, and post-absorptive/post-prandial 
measures of systemic metabolites and regulatory responses to sequential mixed-meal tolerance 
tests (breakfast and lunch) applied pre- and post-intervention. 
 
Experimental Model & Subject Details 
Sampling & Recruitment – This study involved the recruitment of human volunteers and thus 
obtained a favourable opinion from a National Health Service Research Ethics Committee 
(reference: 15/SW/0007). Participants were recruited via local advertisement in the South West 
of the United Kingdom between 2015 and 2018 (trial first advertised May 20th 2015 and first 
participant enrolled June 17th 2015) in order to obtain a total sample of 36 lean and purportedly 





have provided reliable and useful data, so was justified using a priori statistical power estimates 
based on studies of similar duration to have examined the outcome measures in question. For 
example, one study (56) observed a decline in resting metabolic rate following 21 days of daily 
energy restriction (1898 ± 262 versus 1670 ± 203 kcal·day-1), which would therefore have an 
80% probability of detection at p0.05 with n=33. In relation to other outcomes in this study, a 
previous study (57) reported a reduction in 2-hour post-prandial plasma glucose concentrations 
following 10 days of daily energy restriction (10.7 ± 3.6 versus 7.1 ± 3.0 mmol·l-1), in which 
case n=27 would be required to achieve beta 0.8 and alpha 0.05. Collectively, it was therefore 
deemed that ~30 participants would be adequate to detect meaningful treatment effects in the 
present study and recruitment proceeded on a rolling basis until at least 12 had completed each 
experimental condition given that our primary hypotheses concern the physiological responses of 
actually fasting, so a completers-only analysis is appropriate. 
To be eligible upon volunteering, participants had to first be classified as lean based on 
body mass index (BMI; 20.5-24.9 kg·m-2), which was subsequently confirmed upon their first 
laboratory visit using sex-specific fat mass index (FMI) obtained from a dual-energy x-ray 
absorptiometry (DXA) scan. Values of ≤7.5 kg·m-2 and ≤11.0 kg·m-2 were classified as lean for 
males and females, respectively. Further inclusion criteria for this study were that participants 
must be: aged 18-65 years; weight stable (±3 kg) for prior 6 months; able and willing to comply 
with study procedures; willing to undertake required fasting durations; and have the capacity to 
provide informed consent. Exclusion criteria were as follows: body mass >120 kg; engagement 
in fasting practices within 3 months of start date; recent or planned change in diet/physical 
activity habits; evidence of disordered eating as assessed using the EDE-Q 6.0 (Fairburn, 2008); 





treatment which may interfere with study variables; menopausal; pregnant, recently pregnant or 
planning to become pregnant (within 3 months) or currently breastfeeding; having donated blood 
within the last 3 months; lack of capacity/language skills to independently follow the protocol; 
unable to consume test meals due to intolerances/dietary preferences (vegan, gluten, milk 
proteins); or any other behaviour or condition that introduces bias to the experiment or poses 
undue personal risk. Baseline characteristics of the 36 individuals who completed the study are 
reported in table S1. A total of 97 individuals were formally screened for eligibility, of whom 42 
met the inclusion criteria and were consented to complete the first laboratory visit. During the 4-
week baseline monitoring control phase, three individuals withdrew from the trial (citing illness, 
work, or relocation) and two more were excluded from the trial for data outside the inclusion 
criteria (not weight-stable at baseline and implausibly low energy intake). Post-randomization 
only one participant withdrew from the study (0:150 group), citing difficulty fasting. Hence the 
final sample size of completers was n=36 (see supplementary participant flow diagram; fig. S1). 
 
Experimental Design – A randomized controlled trial (www.clinicaltrials.gov NCT02498002; 
trial registered July 15th 2015) with an independent measures, parallel groups design was adopted 
to contrast the effects of intermittent fasting with and without weight-loss relative to standard 
daily energy restriction. Specifically, all volunteers completed a 4-week baseline monitoring 
phase during which they consumed and recorded their habitual diet without consciously 
modifying any aspect of their lifestyle. One week later participants were randomly assigned to a 
4-week dietary intervention using a blocked randomisation scheme with a 1:1:1 allocation and 
stratified according to fat-mass index and physical activity level (PAL), thus ensuring a relatively 





This randomization scheme, including block sizes and sequences, was generated by an individual 
who was not involved in participant recruitment or aware of participant identification codes, with 
details of the allocation sequence concealed from all who were involved with participant 
recruitment and code assignment in order to minimise any risk of bias. Participants completed a 
pre-intervention laboratory visit, after which they received their group assignment and adhered to 
the prescribed dietary intervention for 20 days (with monitoring of free-living diet and physical 
activity during), before a post-intervention laboratory visit to follow-up pre-intervention 
measures. The three experimental conditions were as follows: Daily Energy Restriction (75% 
of habitual diet every 24 hours; 75:75); Alternate-Day Fasting with net Energy Restriction 
(alternating 0% and 150 % of habitual diet every other 24 hours; 0:150); Alternate-Day Fasting 
without net Energy Restriction (alternating 0% and 200% of habitual diet every other 24 hours; 
0:200).   
Protocol – Following the provision of written informed consent, eligibility was initially assessed 
using a series of self–report questionnaires together with a BMI calculation. Eligible participants 
then undertook the 8-week protocol shown in fig. S2. For all laboratory sessions, participants 
abstained from caffeine, alcohol, smoking and strenuous exercise throughout the preceding 24 
hours, and also standardized their dietary intake on a within-participant basis. Following an 
overnight fast (minimum 10 hours), participants reported to the laboratory at 0730 h (± 1 h) 
having consumed 500 ml of water upon waking. For female participants, laboratory sessions 
were scheduled to coincide with the follicular phase of their menstrual cycle (3-10 days after 






Baseline Laboratory Visit 1 – This visit provided a reference point for examining the stability of 
body mass, as an indicator of overall energy balance, throughout the ensuing 4-week 
control/monitoring phase in which habitual dietary intake and physical activity were quantified. 
In addition, this visit served to familiarise participants with key procedures to improve reliability 
over subsequent laboratory sessions. A urine sample was collected when voiding prior to 
measurements of height and body mass to ensure adequate hydration for these measurements 
(urine specific gravity <1.020 and osmolality <900 mOsm). Following a 20-minute rest in a 
semi-recumbent position, resting metabolic rate and substrate oxidation were then measured via 
indirect calorimetry of expired gas samples, after which a fasted blood sample was drawn.  To 
conclude this session, a submaximal treadmill protocol was undertaken to individually calibrate 
the physical activity monitors being used throughout the study (Actiheart, Cambridge 
Neurotechnology). Before departing, participants were given the materials to capture free-living 
measurements of dietary intake and physical activity.  
Control/Monitoring Phase – During this phase, both energy intake and physical activity energy 
expenditure were measured concurrently in four designated monitoring windows of three 
consecutive days each. Each of these windows was separated by at least two days from any other 
and the final window covered the three days leading up to the second laboratory visit to ensure 
compliance with standardisation procedures. Physical activity energy expenditure and intensity 
were measured using individually–calibrated Actiheart monitors and energy intake using a 
weighed record of food and fluid intake. Energy balance was verified by maintaining a stable 
body weight (≤1.0 kg increase or decrease) between the first and second laboratory visits. 
Pre-intervention Laboratory Visit 2 – Participants returned to the laboratory following the 





Adequate hydration status was again ascertained via urinary biomarkers upon arrival prior to 
measuring body mass. Fasting measurements of resting metabolic rate and substrate oxidation 
were then obtained before an intravenous cannula was fitted to an antecubital vein. At this stage, 
an initial venous blood sample was drawn to provide fasted concentrations of relevant 
metabolites and hormones. A small sample of adipose tissue was obtained from volunteers who 
opted-in to that procedure (in which case a repeated venous blood sample was taken afterwards 
to serve as the baseline for the meal response tests). Participants then completed the first of two 
sequential mixed-macronutrient meal tests: a homogenous porridge meal (meal 1; breakfast) and 
a meal-replacement shake (meal 2; lunch). The morning post-breakfast period involved the 
collection of expired gases for indirect calorimetry along with venous blood samples, whereas 
the afternoon post-lunch period only involved blood sampling. 
Intervention Phase – Following pre-intervention laboratory visit 2, a 6-day wash-out period 
occurred prior to commencing the interventions – this was done both to avoid prolonged periods 
of lifestyle monitoring and to maintain an interval of 4 weeks between pre- and post-intervention 
tests. During fasting cycles participants were only permitted water, herbal teas and black 
tea/coffee with no sugar (unsweetened energy-free drinks). During feeding cycles, and 
throughout the daily energy restriction intervention, participants were prescribed the same meals 
as they reported habitually consuming during their baseline monitoring phase but with quantities 
proportionately modified to provide 75%, 150% or 200% of their habitual energy intake. Energy 
intake and physical activity were also monitored over the first and last 6 days of the intervention 
period – the former to quantify compliance and the latter to examine behavioural compensation 





Post-intervention Laboratory Visit 3 – After the completion of 20 consecutive 24-hour dietary 
cycles plus one wash-out day of replicating the standardised diet and activity from before the 
pre-intervention visit, participants returned to the laboratory and repeated the protocol outlined 
earlier for laboratory visit 2. 
Outcome Measures 
Body Composition – Post-void body mass was measured to the nearest 0.1 kg using a 
sliding balance scale (Weylux 424) and height was measured to the nearest 0.1 cm using 
a wall-mounted stadiometer (Seca Stadiometer). Body composition was assessed using a 
DXA scan (QDR Discovery W, Hologic) conducted in accordance with the 
manufacturer’s instructions. Prior to each exposure a quality control procedure was 
executed in which a spine phantom with known radiographic attenuation properties was 
scanned to ensure adequate performance. This was accompanied by a background 
radiographic uniformity test at regular intervals, in which a whole-body scan was 
completed whilst the scanning table was empty to ensure proper functioning and monitor 
changes in background radiation levels. All DXA scans were obtained at the end of data 
collection sessions to provide greater control over hydration status and tissue glycogen 
content. Before scans, participants voided, wore the same lightweight clothing and 
removed shoes along with any heavy items and jewellery. 
Dietary Intake – Participants were provided with a set of compact kitchen scales (Pocket 
Pro 2000, Smart Weigh) and a logbook with which all food and drink items were 
recorded. A member of the research team discussed best practice with participants and 
emphasised the level of detail required. Weighed records were analysed (Nutritics version 





thermogenesis was then estimated based on these self-reported food diaries based on the 
established constants for the thermogenic effect of each macronutrient ingested (58). 
Physical Activity – Physical activity was measured using Actiheart monitors (Cambridge 
Neurotechnology). These monitors were individually calibrated using a treadmill protocol 
involving four 3-minute stages of incremental treadmill locomotion with concurrent 
measurements of heart rate and energy expenditure (indirect calorimetry of expired gas 
samples) to yield a heart rate–physical activity intensity regression equation upon which 
estimates were based. The times at which participants rose in the morning and went to 
bed at night were determined based on visual inspection of individual daily physical 
activity traces to identify when physical movements commenced and ceased at the 
beginning and end of each waking phase (this analysis was completed by an individual 
blinded to treatment allocation). 
Meal Tests – Two successive meal tests were completed pre- and post-intervention. Both 
meals were prescribed to provide one-third of resting metabolic rate, as measured pre-
intervention. Meal 1 was a homogenous porridge meal (1.31 kcal·g-1; 59% carbohydrate, 
29% fat, 12% protein) composed of golden syrup flavour instant oats (Sainsbury’s), 
whole milk (Tesco) and white granulated sugar (Silver Spoon). This was cooked in a 
microwave and cooled for 10 minutes before being consumed in its entirety within a 10-
minute eating opportunity following a pre-meal blood draw. Meal 2 took the form of a 
liquid meal-replacement supplement (1.50 kcal·ml-1; 54% carbohydrate, 30% fat, 16% 
protein) (Ensure Plus; Abbott Nutrition). This was consumed following a pre-meal 
arterialised-venous blood draw within a 5-minute feeding window commencing 3.5 hours 





Indirect Calorimetry – Resting metabolic rate and substrate oxidation were measured 
using indirect calorimetry of expired gas samples (59). In each instance, three consecutive 
5-minute samples were taken in accordance with best practice guidelines (60), with the 
values from two or more samples that agree to within 100 kcal·day-1 taken as an 
arithmetic average. 
Blood Sampling and Analysis – At the pre- and post-intervention visits all blood samples 
were procured by means of an intravenous cannula. To permit the sampling of 
arterialised-venous blood, for 10 minutes prior to arterialised-venous sampling intervals 
participants were asked to place the hand of their cannulated arm into a heated-air box 
(University of Vermont), the internal environment of which was held steady at 55oC. 
Samples were drawn and dispensed into an EDTA-coated tube for processing before the 
cannula was flushed with 0.9 % saline to keep it patent. Analysis of plasma samples for 
concentrations of metabolites was performed using an automated analyser (RX Daytona; 
Randox Laboratories) and commercially available reagents (Randox Laboratories). 
Plasma insulin and leptin concentrations were determined using commercially available 
ELISAs (Mercodia). For the analysis of acylated ghrelin, 1 mL of EDTA-treated whole 
blood was treated with 50 μL of a p-hydroxymercuribenzoic acid solution (prepared as 
100 mM concentrate solution in potassium phosphate buffer containing 1.2 % 10 m-
NaOH). Samples treated in this way were analysed for acylated ghrelin using 
commercially available ELISAs (Merck-Millipore). Total PYY was analysed in plasma 
samples using commercially available ELISAs (Merck-Millipore). Plasma C-terminal 
telopeptide of type I collagen (CTX) concentrations were analysed using commercially 





below the limit of detection for the assay, values were supplanted by the limit of 
detection, as specified by the assay manufacturer. 
Adipose Tissue Sampling and Analysis – Subcutaneous adipose tissue biopsies were 
performed under local anaesthesia (1% lidocaine (lignocaine)) from the area around the 
waist approximately 5 cm lateral to the umbilicus using a 14-G needle using an aspiration 
technique with follow-up biopsies sampled from the opposite side. The sample was 
cleaned with isotonic saline and any clot was manually removed. After weighing the 
sample, it was homogenized in 5 mL of Trizol (Invitrogen) and placed on dry ice before 
being stored at −80°C. Subsequently, samples were defrosted and vortexed, before 0.1 
mL of 1-Bromo-3-Chloropropane per 1 mL of Trizol was added. After shaking the 
mixture vigorously for 30 s, samples were incubated at room temperature for 3 min and 
then centrifuged at 10,000 g for 15 min at 4°C. The aqueous phase was removed and 
mixed with 0.5 mL ice-cold isopropanol per 1 mL of Trizol and stored overnight at -20°C 
to precipitate RNA. Samples were centrifuged at 10,000 g for 10 min at 4°C and the 
supernatant was discarded. The remaining pellet was washed in 1 mL of 75% ethanol per 
1 mL of Trizol and centrifuged at 10,000 g for 10 min. Supernatant was removed once 
more and the pellet was air-dried for 10 min before being suspended in 30 μL of RNase-
free water.  Each sample was quantified by spectrophotometry using a NanoDrop One 
(Thermo Scientific), with 5 ng of total RNA reverse transcribed using a high-capacity 
cDNA reverse transcription kit (SuperScript III, Invitrogen).  A 100 μL reaction mix 
comprising 200 ng of cDNA, 50 μL of Universal Mastermix (Applied Biosystems) and 
RNase-free water, was used for each sample. The following assays, obtained from 





according to manufacturer’s guidance: CLOCK (Hs00231857_m1), CRY1 
(Hs00172734_m1), NPAS2 (Hs00231212_m1), PER1 (Hs00242988_m1), CREB1 
(Hs00231713_m1), APLN (Hs00175572_m1), C/EBP alpha (Hs00269972_s1), C/EBP 
beta (Hs00942496_s1), LEPTIN (Hs00174877_m1), AKT2 (Hs00609846_m1), IRS1 
(Hs00178563_m1), IRS2 (Hs00275843_s1), PIK3R1 (Hs00381459_m1), IGF1R 
(Hs00609566_m1), SIRT1 (Hs01009006_m1), Slc2a4/GLUT-4 (Hs00168966_m1), 
FASN (Hs00188012_m1), MLXIPL/ChREBP (Hs00263027_m1), NAMPT/visfatin 
(Hs00237184_m1), SREBF1/SREBP1C (Hs01088691_m1), PDK4 (Hs01037712_m1), 
ACACA (Hs01046047_m1), ACADM (Hs00936580_m1), ANGPTL4 
(Hs01101127_m1), CIDEC/FSP27 (Hs01032998_m1), CPT1 alpha (Hs00912671_m1), 
FABP4 (Hs01086177_m1), HADHB (Hs01027270_g1), LIPE/HSL (Hs00193510_m10), 
LPL (Hs01012571_m1), PLIN2 (Hs00605340_m1), PNPLA2/ATGL (Hs00386101_m1), 
PNPLA3 (Hs00228747_m1), PPARG (Hs01115513_m1), CIDE-A (Hs00154455_m1), 
IL-6 (Hs00985639_m1), PARP1 (Hs00242302_m1), TNF-a (Hs99999043_m1), 
ADIPOQ/adiponectin (Hs00605917_m1), PRKAA1 (Hs01562315_m1), PRKAA2 
(Hs00178903_m1), PPARGC1A (Hs00173304_m1), SIRT3 (Hs00953477_m1), UCP2 
(Hs01075227_m1). Relative quantification of the genes of interest was performed using 
the comparative CT method as previously described (61). The expression of all these 
genes were first normalized for the geometric mean of PPIA/Cyclophilin A 
(Hs04194521_s1) and PGK1 (Hs99999906_m1) which were used as endogenous controls 
for calculation of ΔCt. The comparative threshold cycle (Ct) method was then used to 
process the data where ΔCt = Ct target gene – Ct endogenous control, with data 





displaying higher Ct values across all genes) for the relevant quantification using ΔΔCt, 
and then to each participant’s own baseline expression of each gene for calculation of the 
relative changes presented in Figure 4. 
Urine Collection and Analysis – Urine samples collected at the outset of each laboratory 
session were analysed for specific gravity via refractometry (SUR-NE Clinical) and 
osmolality via the freezing-point depression method (Micro Osmometer 3300; Advanced 
Instruments). Throughout the 3-hour postprandial period following meal 1, total urine 
output was also collected in order to correct rates of energy and substrate metabolism for 
protein oxidation. Urinary urea concentration was determined using an automated 
analyser, as described above for plasma samples. 
 
Statistical Analysis 
All analysis was performed using SPSS 23.0 (IBM). As specified a priori in our 
published protocol (22), primary contrasts were examined using a 2-way group x time mixed 
model analysis of variance (ANOVA), with experimental condition (group) as a between-
subjects factor and either pre-post visit or control/monitoring-intervention phase (time) as a 
within-subjects factor. Where the time-course of postprandial responses were quantified pre- and 
post-intervention, a three-way ANOVA was utilized to include timepoint in the model (group x 
time x timepoint). Wherever there were multiple contrasts for such timeseries data, the 
Greenhouse-Geisser correction was adopted for epsilon <0.75 and the Huynh-Feldt correction 
adopted for less severe asphericity. This parametric approach was applied irrespective of the 
distribution of data given that the type I error rate of the model is typically close to the nominal 





effects of treatment or interaction effects were followed up using appropriate post-hoc tests to 
identify the location of variance, with a Ryan-Holm-Bonferroni stepwise correction to adjust the 
resulting p-values for multiple comparisons and thus avoid inflation of the type I error rate (63). 
Statistical significance was accepted at p≤0.05 and all data are reported as means  standard 
deviations and standard errors in tables and figures, respectively, with delta change scores (with 






Figure S1. CONSORT flow diagram illustrating progress through each phase of the trial. 
Figure S2. Schematic of the 8-week study design (A) and laboratory sessions 2 and 3 (B). 
Table S1. Participant anthropometric and blood plasma characteristics at baseline. Data are 
meansstandard deviation. 
Table S2. CONSORT reporting checklist 
Data file S1. Primary data. (Excel) 
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Figure Captions:  
Figure 1: Changes in body composition and components of energy balance at baseline and during 
interventions involving either: 25% daily energy restriction diet (75:75); alternate-day fasting with 
50% refeeding for a net 25% energy restriction diet (0:150); or alternate-day fasting with 100% 
refeeding for a net 0% energy restriction diet (0:200). A) Fat and fat-free mass. B) Energy intake C) 
Energy expenditure D) Post-prandial substrate oxidation. E) Physical activity thermogenesis. F) 
Changes in physical activity thermogenesis from baseline. p-values are post-hoc between group 
differences in response [panel A] and post-hoc within group responses [panels B and C]. Data are 
means and standard error of the mean (all conditions n=12). 
Figure 2: Plasma metabolite concentrations in response to breakfast and lunch before and after 
following interventions involving either: 25% daily energy restriction diet (75:75); alternate-day 
fasting with 50% refeeding for a net 25% energy restriction diet (0:150); or alternate-day fasting 
with 100% refeeding for a net 0% energy restriction diet (0:200). A) Glucose. B) Non-esterified 
fatty acids (NEFA). C) Triacylglycerol. D) Glycerol. Data are means and standard error of the 
mean (all conditions n=12).  
Figure 3: Plasma hormone and telopeptide concentrations in response to breakfast and lunch 
before and after interventions involving either: a 25% daily energy restriction diet (75:75); 
alternate-day fasting with 50% refeeding for a net 25% energy restriction diet (0:150); or 
alternate-day fasting with 100% refeeding for a net 0% energy restriction diet (0:200). A) Insulin 





C) Acylated ghrelin (n=11/9/10). D) Peptide yy (tyrosine-tyrosine; n=10/7/7). Data are means 
and standard error of the mean. 
Figure 4: Relative changes in adipose tissue mRNA expression before and after interventions 
involving either: 25% daily energy restriction diet (75:75); alternate-day fasting with 50% 
refeeding for a net 25% energy restriction diet (0:150); or alternate-day fasting with 100% 
refeeding for a net 0% energy restriction diet (0:200). The colour hue and intensity represent the 
direction and effect size (Cohen’s d), respectively, for the pre- to post-intervention change within 
each group (n=8/6/4). Genes with a group x time interaction p≤0.05 are in bold; p-values are 
post-hoc within group responses. 
 
Table Captions:  
Table 1. Body composition responses pre- and post-intervention. Data are meansstandard 
deviation, delta change (95% confidence intervals) for within-group responses and p-values for 
between-group differences in response. 
 
Table 2. Blood plasma responses pre- and post-intervention. Data are meansstandard deviation 
and delta change (95% confidence intervals) for within-group responses and p-values for 






















Table 1. Body composition responses pre- to post-intervention. Data are meansstandard deviation, delta change (95% confidence intervals) for within-group responses 
and p-values for between-group differences in response.  
 Daily Energy Restriction  
(ER; 75:75) 
Alternate-Day Fasting w. net ER 
(0:150) 
Alternate-day Fasting w/o net ER 
(0:200) 
  
   75:75 
p-value 
   0:150 
 
      75:75 
 Pre Δ post  Pre Δ post  Pre Δ post     0:150       0:200        0:200 
Body Mass (kg)a 72.1  10.2 -1.91 (-1.29, -2.54)  72.3  8.2 -1.60 (-0.93, -2.28)  67.7  7.8 -0.52 (0.18, -1.21)  0.46 0.04 0.01 
Body Mass Index (kg·m-2)a 24.0  1.9 -0.6 (-0.5, -0.8)  24.0  2.3 -0.5 (-0.3, -0.8)  23.7  2.1 -0.2 (0.1, -0.4)  0.45 0.03 0.003 
Fat Mass (kg)b 18.3  4.1 -1.75 (-1.25, -2.25)  15.9  5.2 -0.74 (-0.02, -1.24)    17.1  6.7 -0.12 (0.31, -0.55)  0.01 0.05 0.0001 
Fat Mass Index (kg·m-2)b 6.2  1.5 -0.59 (-0.42, -0.76)  5.4  2.2 -0.24 (-0.08, -0.41)  6.0  2.4 -0.01 (0.11, -0.20)  0.01 0.06 0.0001 
Percent Body Fat (%)b 25.7  6.2 -1.81 (-1.25, -2.37)  22.4  7.9 -0.56 (0.12, -1.24)  25.3  9.1 0.10 (-0.45, 0.66)  0.02 0.21 0.001 
Waist Circumference (cm) 84.0  7.1 -2.4 (-1.3, -3.6)  83.2  4.6 -1.7 (-0.5, -2.8)  80.0  7.9 -0.7 (0.6, -1.9)  0.42 0.42 0.09 
Visceral Fat Mass (g) 383  164 -31 (-12, -51)  356  95 -34 (-13, -56)  311  162 -8 (33, -48)  0.81 0.65 0.65 
Fat-Free Mass (kg) 53.0  10.3 -0.03 (0.40, -0.47)  55.4  9.8 -0.75 (0.09, -1.59)  49.5  8.8 -0.53 (0.004, -1.06)  0.35 0.64 0.35 
Lean Soft Tissue Mass (kg) 50.3  10.0 -0.03 (0.40, -0.45)  52.6  9.4 -0.74 (0.09, -1.57)  47.0  8.4 -0.52 (0.01, -1.06)  0.33 0.33 0.63 
Bone Mineral Content (g) 2676  431 -8.5 (30.8, -47.8)  2747  453 -6.6 (26.3, -39.4)  2499  428 -5.9 (18.9, -30.8)  >0.99 >0.99 >0.99 
Bone Mineral Density (g·cm-3) 1.20  0.10 -0.004 (0.01, -0.18)  1.23  0.11 -0.01 (0.01, -0.02)  1.18  0.10 -0.01 (-0.004, -0.03)  >0.99 >0.99 >0.99 
a  denotes significant group x time (pre-post) interactions at p=0.01 
b  denotes significant group x time (pre-post) interactions at p=0.0001 
Within-group responses where the confidence interval does not include zero are in bold text; between group p-values are independent t-tests, adjusted for multiple comparisons. 





















Table 2. Blood plasma responses pre- to post-intervention. Data are means±standard deviation and delta change (95% confidence intervals) for within-group responses  
and p-values for between-group differences in response.   
 Daily Energy Restriction  
(ER; 75:75) 
Alternate-Day Fasting w. net ER 
(0:150) 
Alternate-day Fasting w/o net ER 
(0:200) 
  
   75:75 
p-value 
   0:150 
 
      75:75 
 Pre Δ post  Pre Δ post  Pre Δ post     0:150       0:200        0:200 
Glucose (mmol·l-1) 5.27 ± 0.38 0.01 (-0.13, 0.15)  5.62 ± 0.37 0.04 (-0.29, 0.38)  5.14 ± 0.67 0.10 (-0.20, 0.40)  >0.99 >0.99 >0.99 
iAUCa Meal1 (mmol·l-1·180 min) 136 ± 103 26.8 (-29.9, 83.4)  106 ± 68 9.9 (-75.1, 94.9)  90 ± 30 0.8 (-22.8, 24.5)  >0.99 >0.99 >0.99 
iAUCa Meal2 (mmol·l-1·120 min) 197 ± 65 -1.8 (26.7, -30.2)  196 ± 90 1.5 (-47.5, 50.4)  176 ± 72 -0.9 (21.2, -23.0)  >0.99 >0.99 >0.99 
Insulin (pmol·l-1) 20.6 ± 8.2 -3.5 (1.0, -7.9)  19.0 ± 5.0 -0.01 (4.7, -4.7)  18.5 ± 5.8 2.7 (-2.1, 7.5)  0.52 0.52 0.16 
iAUCa Meal1 (nmol·l-1·180 min) 13.1 ± 4.9 1.0 (-3.2, 5.2)  17.9 ± 7.8 2.5 (-4.0, 8.7)  18.5 ± 8.0 0.3 (-3.6, 4.3)  >0.99 >0.99 >0.99 
iAUCa Meal2 (nmol·l-1·120 min) 14.9 ± 5.4 -0.1 (3.1, -3.3)  16.7 ± 6.0 0.3 (-1.2, 1.9)  20.2 ± 11.3 -0.5 (5.1, -6.0)  >0.99 >0.99 >0.99 
HOMA2-IRb 0.46 ± 0.18 -0.08 (0.02, -0.17)  0.43 ± 0.11 -0.004 (0.10, -0.11)  0.40 ± 0.11 0.06 (-0.04, 0.16)  0.52 0.52 0.12 
NEFAc (mmol·l-1) 0.48 ± 0.34 -0.02 (0.08, -0.13)  0.33 ± 0.09 0.01 (-0.08, 0.09)  0.34 ± 0.18 -0.04 (0.09, -0.16)  >0.99 >0.99 >0.99 
AUCa (mmol·l-1·330 min) 49.7 ± 21.1 -3.8 (5.0, -12.7)  39.7 ± 10.7 -0.1 (6.6, -6.8)  41.5 ± 17.6 -2.1 (8.9, -13.0)  >0.99 >0.99 >0.99 
Glycerol (µmol·l-1) 58.0 ± 32.9 -0.39 (18.5, -19.3)  40.6 ± 29.9 0.44 (-16.0, 16.9)  35.9 ± 24.5 -1.75 (14.7, -18.2)  >0.99 >0.99 >0.99 
AUCa (mmol·l-1·330 min) 12.3 ± 5.0 1.7 (-0.8, 4.2)  10.7 ± 4.1 0.3 (-1.1, 1.7)  10.7 ± 4.1 -0.1 (1.3, -1.6)  0.60 0.63 0.54 
Triacylglycerol (mmol·l-1) 0.81 ± 0.32 -0.04 (0.13, -0.21)  0.97 ± 0.33 -0.12 (0.02, -0.27)  0.92 ± 0.32 -0.02 (0.13, -0.18)  >0.99 >0.99 >0.99 
AUCa (mmol·l-1·330 min)e 236 ± 109 38.5 (-3.1, 80.2)  384 ± 126 -46.7 (1.1, -94.4)  345 ± 165 -5.0 (40.4, -50.4)  0.02 0.27 0.27 
Total Cholesterol (mmol·l-1) 4.75 ± 0.97 -0.28 (-0.09, -0.48)  4.74 ± 0.77 0.00 (-0.23 ,0.23)  4.68 ± 0.96 0.01 (-0.24, 0.27)  0.16 0.94 0.16 
HDLd Cholesterol (mmol·l-1) 1.64 ± 0.43 -0.07 (0.03, -0.18)  1.53 ± 0.43 0.05 (-0.04, 0.14)  1.60 ± 0.41 0.04 (-0.05, 0.13)  0.21 0.91 0.21 
LDLd Cholesterol (mmol·l-1) 2.96 ± 0.93 -0.24 (-0.07, -0.41)  3.06 ± 0.85 -0.10 (0.12, -0.31)  2.82 ± 1.18 -0.02 (0.27, -0.31)  0.55 0.66 0.53 
Leptin (µg·l-1)e 9.3 ± 6.0 -3.8 (-1.5, -6.1)  10.5 ± 13.9 -2.8 (0.4, -6.0)  16.4 ± 15.9 0.2 (-1.3, 1.7)  0.59 0.16 0.01 
Adiponectin (mg·l-1) 9.9 ± 2.6 -0.7 (-0.3, -1.2)  8.8 ± 2.6 -0.3 (0.3, -0.6)  10.5 ± 4.9 -0.2  (1.0, -1.5)  0.21 0.97 0.87 
a iAUC = incremental area under the curve from concentrations prior to each Meal (i.e. Breakfast and Lunch); AUC = total area under the curve across both meals. 
b HOMA-IR = Homeostatic Model Assessment of Insulin Resistance 2 (64) 
c NEFA = Non-Esterified Fatty Acids 
d HDL/LDL = High-/Low-Density Lipoprotein 
e denotes significant group x time (pre-post) interactions at p≤0.05 
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